日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Racial Disparities in Non-Stigmatized Supportive Care Medication Use in Pancreatic Cancer

胰腺癌非歧视性支持治疗药物使用中的种族差异

Kweyete, Olga Monika Trejos; Whitner, Chardaé; Deremer, David L; Guo, Yi; Bian, Jiang; Scarton, Lisa; Rogers, Sherise C; Wilkie, Diana J; Lou, Xiwei; Allen, John M

Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

更正:PARP抑制剂尼拉帕尼治疗BAP1和其他DNA损伤反应通路缺陷型肿瘤的II期试验

George, Thomas J; Lee, Ji-Hyun; DeRemer, David L; Hosein, Peter J; Staal, Steven; Markham, Merry Jennifer; Jones, Dennie; Daily, Karen C; Chatzkel, Jonathan A; Ramnaraign, Brian H; Close, Julia L; Ezenwajiaku, Nkiruka; Murphy, Martina C; Allegra, Carmen J; Rogers, Sherise; Zhang, Zhongyue; Li, Derek; Srinivasan, Gayathri; Shaheen, Montaser; Hromas, Robert

Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival

胰腺癌恶病质:影响生活质量和生存率的新见解

Yoon, Saunjoo L; Grundmann, Oliver; Rogers, Sherise; Schlaeger, Judith M; Han, Bo; Agyare, Edward; Wilkie, Diana J

ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer.

ECM 硬度诱导的氧化还原信号增强硬脂酰吉西他滨在胰腺癌中的疗效

Zhao Shuqing, Agyare Edward, Zhu Xueyou, Trevino Jose, Rogers Sherise, Velazquez-Villarreal Enrique, Brant Jason, Eliahoo Payam, Barajas Jonathan, Hoang Ba Xuan, Han Bo

Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study

晚期结直肠癌临终关怀中镇痛药和精神药物使用方面的种族差异:一项回顾性队列研究

Allen, John M; Trejos Kweyete, Olga M; Guo, Yi; Bian, Jiang; Lou, Xiwei; Rogers, Sherise C; Scarton, Lisa; DeRemer, David L; Wilkie, Diana J

A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer

一种新型吉西他滨类似物作为潜在抗癌药物:合成及体外抗胰腺癌活性评价

Okoro, Joy; Bulusu, Raviteja; Frimpong, Esther; Zhu, Xue; Rogers, Sherise; Agyare, Edward

Executing plans to enhance diversity across cancer centers in the United States: opportunities and challenges

在美国癌症中心推行提升多样性计划:机遇与挑战

Li, Christopher I; Rogers, Sherise Chantell; Bult, Carol J; Guerra, Carmen E; Talton, Angela; Williams, Lovoria B; Law, Wendy

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

PARP抑制剂尼拉帕尼治疗BAP1和其他DNA损伤反应通路缺陷型肿瘤的II期临床试验

George, Thomas J; Lee, Ji-Hyun; DeRemer, David L; Hosein, Peter J; Staal, Steven; Markham, Merry Jennifer; Jones, Dennie; Daily, Karen C; Chatzkel, Jonathan A; Ramnaraign, Brian H; Close, Julia L; Ezenwajiaku, Nkiruka; Murphy, Martina C; Allegra, Carmen J; Rogers, Sherise; Zhang, Zhongyue; Li, Derek; Srinivasan, Gayathri; Shaheen, Montaser; Hromas, Robert

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience

肽受体放射性核素疗法治疗神经内分泌肿瘤的安全性和有效性:单中心经验

Sukrithan, Vineeth; Armbruster, Heather; Rogers, Sherise; Vogt, Sherry Mori; Grenade, Cassandra; Verschraegen, Claire; Zhou, Ye; Goyal, Ashima; Natwa, Mona; Hussein, Akram; Barr, Hallie; Konate, Dramane; Batdorf, Rochelle; Brown, Andrew; Williams, Bonnie; Zhao, Songzhu; Wei, Lai; Xu, Menglin; Shah, Manisha H; Konda, Bhavana

Clinician-patient communication about cancer treatment misinformation: The Misinformation Response Model

临床医生与患者就癌症治疗错误信息进行的沟通:错误信息应对模型

Mullis, M Devyn; Fisher, Carla L; Johnson, Skyler B; Liu, Tianshi; Amin, Tithi B; Rogers, Sherise; DeGruccio, Kennan; Bylund, Carma L